Two out of 235. That's how many adolescents on eight-weekly HIV injections saw their virus rebound over nearly two years, compared with 15 out of 241 taking a daily pill instead. The gap, reported in a randomized trial published in The Lancet, is large enough that researchers are now pushing for these injections to become standard care for young people living with HIV across sub-Saharan Africa, not just an occasional alternative.

The LATA trial, short for Long-Acting Treatment in Adolescents, enrolled 476 participants aged 12 to 19 across five clinics in Kenya, South Africa, Uganda, and Zimbabwe. It's the kind of result that could reshape how a historically difficult-to-treat population manages a lifelong condition, and it arrives with unusually clean numbers behind it.

A trial built for a population medicine has struggled with

Every participant entered the study already doing well on treatment: all had undetectable viral loads, had been on daily antiretroviral tablets for more than a year, and had never experienced a treatment failure. Almost all had acquired HIV at birth, according to the trial's published enrollment data, meaning they'd typically been managing a daily pill regimen since childhood, often for over a decade.

That baseline matters, because adolescents living with HIV have historically fared worse on antiretroviral therapy than adults do, a gap researchers have struggled for years to close. Participants were randomly split between two groups: one continued standard daily oral therapy, while the other switched to injections of cabotegravir and rilpivirine, two long-acting HIV medicines, administered initially at weeks 4, 8, and 16, then every eight weeks after that.

What the head-to-head results actually showed

After 96 weeks of follow-up, the difference between the two groups was stark. Only two participants in the injectable group, roughly 1%, had a confirmed viral load of 50 copies per milliliter or higher, the threshold researchers used to define rebound. In the daily-pill group, 15 participants, about 6%, crossed that same threshold, according to the trial results published in The Lancet.

That's not a marginal advantage. A sixfold difference in rebound rates is the kind of result that tends to change clinical guidelines, particularly when it comes from a randomized, controlled trial design rather than observational data. Median follow-up across the study ran to 120 weeks, giving researchers a solid window to confirm the pattern held over time rather than reflecting a short-term fluke.

Why daily pills fail teenagers specifically

Professor Sarah Pett of the UCL Innovative Clinical Trials Unit, the trial's chief investigator, explained the underlying problem in blunt terms. "HIV-positive adolescents as a group have historically done worse on antiretrovirals compared to adults. There is bullying and stigma associated with taking pills every day," she said, according to reporting from the Press Trust of India.

That stigma isn't a minor side detail, it's a primary driver of treatment failure in this age group. A daily pill requires a daily, often visible, reminder of an HIV diagnosis that many adolescents are actively trying to keep private from classmates, friends, or even extended family. Missing doses to avoid that visibility, or simply due to the friction of maintaining a strict daily routine as a teenager, is a well-documented pattern that long-acting injectables sidestep almost by design.

A result stronger than what adults have shown

What makes the LATA findings particularly notable is how they compare to prior research in adult populations. Pett was explicit about that contrast: "The benefits of this form of treatment for adolescents is stronger than we have seen for adults. Previous trials in adults have shown only that injectables are no less effective than tablets," she said.

In other words, earlier adult trials treated injectable therapy as a non-inferiority story, proving it wasn't worse than pills, without necessarily proving it was better. LATA flips that framing for adolescents specifically: injections didn't just match daily tablets, they meaningfully outperformed them. That's a much stronger basis for changing how clinicians approach treatment for this age group, rather than simply offering injectables as a lateral option.

The regulatory and access landscape right now

The World Health Organization currently recommends long-acting injectables as an "alternative" option for adults and adolescents who are already taking daily tablets, have successfully suppressed their HIV, and don't have active hepatitis B. That framing, alternative rather than preferred, reflects the more cautious evidence base that existed before this trial. Pett said the LATA findings support expanding availability of injectable treatment specifically for adolescents, a more targeted policy push than a blanket recommendation across all age groups.

In the United States, this isn't a hypothetical future treatment. Adolescents aged 12 and older can already be prescribed injectable cabotegravir and rilpivirine, according to UCL. The bigger question the LATA trial actually addresses is access in the lower-income settings where the vast majority of adolescents living with HIV actually live, precisely the sub-Saharan African countries where this trial was conducted.

The practical barriers standing in the way

Even strong clinical results don't automatically translate into widespread access. Cost, cold-chain refrigeration requirements for the injectable medicines, and the logistics of ensuring patients return to a clinic every eight weeks rather than simply picking up a pill bottle are all real barriers in the settings where this treatment could do the most good. The trial was funded by the European Union's EDCTP2 program and Johnson & Johnson Innovative Medicines, with Johnson & Johnson supplying injectable rilpivirine and ViiV Healthcare supplying injectable cabotegravir, an indication of the kind of coordinated public-private funding this expansion would likely continue to require.

Pett's team framed the path forward as much a systems challenge as a clinical one: closing the gap between what a trial can prove works and what a public health system in Kenya, South Africa, Uganda, or Zimbabwe can actually deliver reliably to hundreds of thousands of adolescents, not just the 476 enrolled in this study.

Why this result matters beyond the trial itself

Adolescents represent a sizable and growing share of the global HIV-positive population, particularly in sub-Saharan Africa, where mother-to-child transmission before widespread prevention programs left many of today's teenagers living with a lifelong diagnosis they never chose. A treatment option proven to work meaningfully better for exactly this group, in exactly this region, addresses one of the more stubborn gaps in decades of HIV treatment progress.

Whether the LATA trial's findings translate into changed WHO guidance, expanded funding, or faster rollout across the clinics that need it most will likely take longer to resolve than the trial itself did. But for a 6% failure rate on daily pills to drop to 1% with injections given every two months, the clinical case for making that shift happen faster is now about as clear as trial data gets.